Provided by Tiger Fintech (Singapore) Pte. Ltd.

AstraZeneca PLC

77.69
+0.13000.17%
Post-market: 77.750.0600+0.08%17:31 EDT
Volume:4.66M
Turnover:362.13M
Market Cap:240.95B
PE:29.27
High:78.08
Open:77.19
Low:77.07
Close:77.56
52wk High:82.41
52wk Low:61.24
Shares:3.10B
Float Shares:3.09B
Volume Ratio:1.35
T/O Rate:0.15%
Dividend:1.57
Dividend Rate:2.01%
EPS(TTM):2.65
EPS(LYR):2.27
ROE:19.67%
ROA:8.28%
PB:5.39
PE(LYR):34.23

Loading ...

AstraZeneca Slips Wednesday, Underperforms Market

Dow Jones
·
Aug 07

US Health Department Ending Federal mRNA Vaccine Development

MT Newswires Live
·
Aug 06

SOPHiA GENETICS Expanding Collaboration With AstraZeneca Focused on Breast Cancer

MT Newswires Live
·
Aug 05

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time -- WSJ

Dow Jones
·
Aug 03

AstraZeneca PLC ADR Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Aug 02

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

Dow Jones
·
Aug 01

EU-US Trade Deal: A Win for Trump?

TradingKey
·
Aug 01

European Pharma Shares Fall After Trump Asks For Drug Price Cuts -- Market Talk

Dow Jones
·
Aug 01

AstraZeneca Falls Thursday, Underperforms Market

Dow Jones
·
Aug 01

Top Midday Stories: US June Advance Trade Gap Narrows; Novo Nordisk Q2 Earnings Miss Estimates, Names New CEO

MT Newswires Live
·
Jul 29

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-07-29

Reuters
·
Jul 29

Earnings Movers | Celestica Jumps 18%; Cadence Design, Philips Rise 10%; AstraZeneca Gains 3%; Merck Sinks 5%; PayPal Drops 8%

Tiger Newspress
·
Jul 29

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

Benzinga
·
Jul 29

AstraZeneca's Drug Pipeline to Be in Focus -- Market Talk

Dow Jones
·
Jul 29

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

Dow Jones
·
Jul 29

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

Dow Jones
·
Jul 29

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

Dow Jones
·
Jul 29

AstraZeneca Shares Look Undervalued -- Market Talk

Dow Jones
·
Jul 29

AstraZeneca Reaffirms 2025 Guidance: Expects High Single-Digit Revenue Growth, Low Double-Digit Core EPS Growth, And 18–22% Core Tax Rate

Benzinga
·
Jul 29

AstraZeneca Q2 Adj. EPS $1.08 Misses $1.10 Estimate, Sales $14.46B Beat $14.07B Estimate

Benzinga
·
Jul 29